NASDAQ NMS - GLOBAL MARKET · KPRX
-0.78% · -$0.0200 · Vol 3.4K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals Inc

Pharmaceuticals
$2.56
Card
Relationship Map

Follow $KPRX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KPRX by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
KPRX
Kiora Pharmaceuticals Inc
Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

75/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Fri Oct 2 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KPRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KPRX catalysts
About Kiora Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
13
Country
US

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.55
Day high
$2.56
Day low
$2.55
Previous close
$2.58
52W high
$2.86
-10.49% from high
52W low
$1.80
72% of range
Market cap
$11.3M
EPS
$-2.4723
Beta
-0.26
Shares out
4.4M
Volume
3.4K
0.26× rel vol
Avg volume
13.4K
VWAP
$2.55
Price history computed in-house
1W
-2.66%
1M
+0.39%
3M
-2.66%
1Y
-6.91%
YTD
+29.95%
SMA 50 $2.60 · below
SMA 200 $2.39 · above
52W position 72%

KPRX overview

Veridion Score
75
Registered · 2026-10-02
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KPRX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KPRX Form 4 filings
Public disclosures

Congress activity in KPRX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for KPRX in the cached public ledger.

Federal contracts

KPRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KPRX in this window.
Lobbying spend

KPRX lobbying filings, year to date.

Registered lobbying filings matched to Kiora Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KPRX in this window.
Loading news for KPRX
Analyst ratings
Sovereign unlock shows live analyst consensus for KPRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.